3 Days
Source:
الصحة والعلوم الشرق الأوسط
Early Monjaro use may reduce diabetes symptoms
A study funded by Eli Lilly revealed that patients with type 2 diabetes who tried the drug Terzipatide, commercially known as Monarcho, experienced significant improvements in blood sugar control and weight over a two-year period, compared to those using other medications from the GLP-1 class. The results showed that approximately 60% of patients who received Monarcho had normal blood sugar levels, compared to 24% in the control group. The study indicates that early use of this medication may offer greater and more sustainable benefits in managing the disease.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)